SCHEMBL3451632

SCHEMBL3451632

O=C(O)c1cc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2N2CCOCC2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPK9 P45984 1/20 0.44
▸ MAPK10 P53779 1/20 0.44
▸ BTK Q06187 1/20 0.43
▸ SMG1 Q96Q15 2/20 0.43
▸ SYK P43405 3/20 0.43
▸ JAK2 O60674 3/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ AURKA O14965 2/20 0.42
▸ AURKB Q96GD4 2/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ TYK2 P29597 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ PIK3CA P42336 2/20 0.42
▸ MTOR P42345 2/20 0.42
▸ PKMYT1 Q99640 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348458 0.91 NPC1 (0.49) TDO2SMN1; SMN2NPC1RAB9AMAPK9
SCHEMBL3451095 0.87 MEN1 (0.49) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3451664 0.86 MAPK1 (0.46) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3450200 0.86 SMN1; SMN2 (0.44) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3449885 0.84 TDO2 (0.46) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3451420 0.84 SMN1; SMN2 (0.48) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3450635 0.84 SYK (0.41) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3450398 0.84 PIK3CA (0.41) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3451601 0.84 BTK (0.42) TDO2SMN1; SMN2NPC1RAB9ATSHR
SCHEMBL3350959 0.84 SMN1; SMN2 (0.55) TDO2SMN1; SMN2NPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD TDO2 1735/4885SMN1; SMN2 3328/4885NPC1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback